Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray Eisai wraps filing for Biogen-partnered Aduhelm follow-up, hoping to regain 'credibility and trust' The top 10 highest paid biopharma R&D executives in 2021 Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name More Moma: $150M series B will push precision cancer drugs to clinic by 2024 Adimab swaps scientist for lawyer as CEO Tillman Gerngross steps down after 15 years Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication Scientists may have inadvertently discovered how to reverse a central protein pitfall that causes dementia Moneybags Nuvation deprioritizes 2 solid tumor prospects to narrow focus onto 3 candidates Antibody therapies could penetrate pancreatic cancer's shield if research pays off Pfizer buys migraine partner Biohaven for $11.6B, betting on CGRP drugs in grand return to neuroscience Senators seek to reauthorize mental health reforms, grants in latest bid to improve access FDA clears its first in vitro test for the early Alzheimer’s detection IllumiCare consultation app takes hassle out of connecting patients to trials Featured Story | By Max Bayer Biotech deal making has received a much-needed shot in the arm as Pfizer coughed up $11.6 billion for Biohaven, including its late-stage migraine nasal spray. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Eisai has plowed through the debate surrounding the accelerated approval pathway to fully deliver its latest Biogen-partnered Alzheimer’s disease med, lecanemab, to the FDA for swift consideration. read more By Max Bayer The top 10 list of the highest-paid biopharma R&D execs looks a little bit different in 2021 than the year before after a number of pendulum swings in pay. And the new top 2 earners have since left their top research posts for CEO roles elsewhere. read more By Gabrielle Masson Despite past troubles tied to its lead drug, Cortexyme is forging ahead with new leadership, the acquisition of skeletal-focused biotech Novosteo and even a name change on the horizon. read more By Gabrielle Masson With all initial investors returning for more, Moma Therapeutics just closed out a $150 million series B funding round to move multiple precision oncology programs closer to clinic. read more By James Waldron Adimab will be swapping a scientist for a lawyer to lead the bispecific-antibody-focused biotech, as Tillman Gerngross steps down after 15 years at the helm. read more By Nick Paul Taylor Idorsia has suffered another setback in the clinic. A phase 2a trial of the selective orexin-1 antagonist ACT-539313 in binge eating disorder missed the mark, prompting the Actelion spinout to give up on the indication. read more By Max Bayer A global team of scientists may have inadvertently discovered a potential treatment for one of the root causes of dementia. The researchers say when under stress, the endoplasmic reticulum actually reversed the build-up of protein "aggregates" caused by misfolding, a mechanism that can result in neurodegenerative diseases. read more By Nick Paul Taylor Nuvation Bio is narrowing its focus. Having gone into the year planning to advance a pair of solid tumor programs toward the clinic, the biotech has now deprioritized the candidates to focus on its three other assets. read more By James Waldron New research in mice has shed light on how antibodies could be harnessed to puncture the shield of scarlike cells that protect pancreatic cancer from treatment. read more By Angus Liu Pfizer is channeling its large COVID-19 windfall into dealmaking, buying Biohaven's CGRP migraine portfolio for $11.6 billion six months after partnering up on ex-U.S. markets for marketed med Nurtec. read more By Robert King A bipartisan duo of senators introduced legislation to reauthorize several key mental health programs, the latest reform Congress is exploring to improve access. read more By Conor Hale The FDA said the Lumipulse test developed by Fujirebio Diagnostics could allow some patients to skip PET brain scans for finding amyloid plaques. read more By Gareth Macdonald Consultations are an untapped trial recruitment opportunity, according to tech firm IllumiCare, which is betting that a new app can help inform potential participants about studies. read more Resources Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next Gen June 29-30, 2022 | Free Virtual Event Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 